# Global Benchmark for Efficient Drug Pricing (GLOBE) Model

**Action Urgency Score:** 90/100

| Field | Value |
|---|---|
| Agency | Health and Human Services Department; Centers for Medicare & Medicaid Services |
| Type | Final rule |
| Action | Final rule. |
| Published | 2026-10-02 |
| Effective | 2026-11-30 |
| Significant | Yes (EO 12866) |
| CFR parts | 42 CFR 513 |
| Summary | This final rule implements the Global Benchmark for Efficient Drug Pricing Model (GLOBE Model), a new mandatory Medicare payment model under section 1115A of the Social Security Act. The GLOBE Model will test whether a payment model that uses an alternative method for calculating Medicare Part B drug inflation rebate amounts for certain separately payable Medicare Part B drugs and biological products reduces costs for Original Medicare (OM) beneficiaries and the Medicare program while preserving quality of care. The term OM has the same meaning as Medicare fee-for-service and the traditional M |
| Document number | 2026-20281 |

## Why this score
- Effective date within 30 days.
- Significant rule under EO 12866.
- Final rule.

Source: Federal Register API (Office of the Federal Register) (https://www.federalregister.gov/documents/2026/10/02/2026-20281/global-benchmark-for-efficient-drug-pricing-globe-model). Last refreshed: 2026-11-04T21:40:49.974Z.
Data from the Federal Register API; the published Federal Register document is authoritative. Informational only, not legal advice.